Neurodrug Partnership Azevan is developing SRX246 for Huntington's disease neuropsychiatric symptoms, indicating strong potential for collaboration with CNS focused CROs and pharma partners on clinical development, regulatory strategy, and possible licensing opportunities.

Outsourcing Needs With a small team and revenue in the low millions, Azevan is likely to rely on outsourcing for R&D, manufacturing, and regulatory work. This presents opportunities for CROs, contract manufacturers, and analytical testing providers to offer integrated services.

China Partnerships Based in China, the company could benefit from local manufacturing and regulatory support. Partnerships with Chinese contract manufacturers, labs, and regulatory consultancies may accelerate development and reduce time to market in Asia.

Digital Modernization The tech stack suggests room for web and digital marketing enhancements. Offering website modernization, search engine optimization, CRO oriented customer portals, and analytics could improve visibility, investor outreach, and candidate recruitment.

Funding and Licensing With limited revenue, Azevan may be open to licensing SRX246, co development, or venture funding. Presenting deal structures for asset licensing, milestone partnerships, and grant funding could align with their growth trajectory.